Literature DB >> 9577049

The use of naltrexone to treat ambulatory patients with alcohol dependence.

N J Galarza1, D Díaz Ramírez, F Guzmán, J A Caballero, A J Martínez.   

Abstract

UNLABELLED: The purpose of this study is to evaluate the efficacy of Naltrexone in decreasing craving symptoms among Puerto Rican male veterans with alcohol dependence.
METHOD: This is a double blind placebo control study with a convenience sample of eleven patients divided in two groups (placebo and Naltrexone). Scales consisting of Zung Depression, Zung Anxiety, MMSE, OCD Screener, Craving, and Somatization were administered at baseline, and weekly for four weeks as follow up.
RESULTS: There were no statistically significant differences between the two groups on any of the outcome variables at baseline or follow up measurements. A statistical trend was noted toward a decrease in somatization. A decrease in craving symptoms was observed in the experimental group.
CONCLUSIONS: Even though our results did not show evidence of the efficacy of Naltrexone in decreasing craving symptoms, a small number of patients did benefit from the medication. The results could have been affected by the small sample size.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9577049

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  3 in total

Review 1.  Naltrexone: A Pan-Addiction Treatment?

Authors:  Elias Aboujaoude; Wael O Salame
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

2.  Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations.

Authors:  Cristina M López; Simone C Barr; Kathryn Reid-Quiñones; Michael A de Arellano
Journal:  J Stud Alcohol Drugs       Date:  2017-05       Impact factor: 2.582

Review 3.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.